LSL Pharma Group Inc.
LSL.V
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 22.07% | -157.66% | 8.23% | -204.66% | -160.37% |
| Total Depreciation and Amortization | 28.99% | 10.55% | 20.64% | -13.89% | 55.70% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 67.27% | 141.63% | -199.63% | 129.02% | 25.60% |
| Change in Net Operating Assets | 148.57% | -174.72% | 153.76% | -1,357.55% | 132.58% |
| Cash from Operations | 131.26% | -465.38% | 121.70% | -398.58% | 419.41% |
| Capital Expenditure | -61.62% | 30.52% | 58.70% | -93.84% | -22.03% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -51.76% | 58.08% | -95.94% | -31.78% | -115.72% |
| Cash from Investing | -54.63% | 80.32% | -169.93% | -59.50% | -60.63% |
| Total Debt Issued | -69.65% | -34.72% | 4.98% | 49.08% | 195.74% |
| Total Debt Repaid | -0.82% | 84.33% | 52.26% | -1,121.16% | -24.26% |
| Issuance of Common Stock | -- | -- | -98.20% | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -35.56% | 64.84% | -52.53% | -50.97% | -83.75% |
| Cash from Financing | -91.59% | 35.50% | 129.52% | -65.72% | 344.99% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -10.60% | 121.83% | 102.16% | -194.75% | 4,277.93% |